Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib

Background: Carfilzomib’s (Cfz) adverse events in myeloma patients include cardiovascular toxicity. Since carfilzomib’s vascular effects are elusive, we investigated the vascular outcomes of carfilzomib and metformin (Met) coadministration. Methods: Mice received: (i) saline; (ii) Cfz; (iii) Met; (i...

Descripción completa

Detalles Bibliográficos
Autores principales: Efentakis, Panagiotis, Doerschmann, Hendrik, Witzler, Claudius, Siemer, Svenja, Nikolaou, Panagiota-Efstathia, Kastritis, Efstathios, Stauber, Roland, Dimopoulos, Meletios Athanasios, Wenzel, Philip, Andreadou, Ioanna, Terpos, Evangelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432349/
https://www.ncbi.nlm.nih.gov/pubmed/32707866
http://dx.doi.org/10.3390/ijms21155185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432349/
https://www.ncbi.nlm.nih.gov/pubmed/32707866
http://dx.doi.org/10.3390/ijms21155185

Ejemplares similares